Clinical Trial

Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma

Study acronym: SURVEILL'ORL

Active, Not Recruiting Phase 3

Summary

Phase III randomized trial to compare the efficacy in terms of overall survival of two follow-up strategies (conventional versus intensive) among smokers and/or alcohol drinkers patients, older than 35 year, in complete remission 2-4 months after treatment of head and neck squamous cell carcinoma Patients will be randomized after the post-treatment check-up (clinical examination and reference imaging including PET-CT for patients ≥ N2) performed 2 to 4 months after the end of treatment. The randomization ratio is 1:1.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2018-04-26; most recent amendment 2026-03-25.

Status change: Recruiting → Active, Not Recruiting 2023-01-19

Trial Details

NCT Number	NCT03519048
Lead Sponsor	Gustave Roussy, Cancer Campus, Grand Paris Collaborators: National Cancer Institute, France
Conditions	Head and Neck Squamous Cell Carcinoma
Enrollment	197 participants
Start Date	2018-01-17
Primary Completion	2031-01 (estimated)
Study Completion	2031-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-30